It is also worth mentioning that some preclinical findings have suggested that the pre-treatment of HER2-overexpressing breast cancer cells with trastuzumab before the administration of E75 vaccines resulted in greater expansion and increased specific cytotoxicity of stimulated CTLs, suggesting that a combination of passive and active immunotherapy may have a synergistic effect. This evidence concerns the gene ERBB2 and breast carcinoma.